Skip to main content

CCTG Connection


Published:
Category: Group updates
CCTG Annual Spring Meeting of Participants Friday, May 3 to Sunday, May 5
If you are planning meetings and/or attending the Spring Meeting, be sure to read your Invitation carefully so you are clear on the the funding support associated with your Invitation. Read More
Published:
Category: Publications
NEJM publication - A simple hysterectomy is considered a safe option for low-risk early-stage cervical cancer patients and improves quality of life.

The results of the CX5/SHAPE clinical trial, published today in the New England Journal of Medicine (NEJM), conclude that a simple hysterectomy is a safe treatment option for women with low-risk early-stage cervical cancer. The Phase III international trial compared radical hysterectomy and pelvic node dissection with simple hysterectomy and pelvic node dissection.

Read More
Published:
Category: Publications
Publication: CRC5
CRC5 Publication: HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB 
 
Battaglin F, Ou F-S, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Ashouri K, Zemla TJ, Blanke CD, Venook AP, Kabbarah O, Lenz H-J, Innocenti F. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405 (ONLINE). Journal of Clinical Oncology 2024.
Read More
Published:
Category: Trials
Closed to Accrual: BRC7
CCTG BRC.7 INSIGNA: A Randomized, Phase III Study of First line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis  was officially closed to further accrual after meeting its accrual goal with CCTG centres contributing 50 patients to the study, 8% of the final accrual of 607.
 
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or
Read More
Published:
Category: Trials
permanent closure of the ALC3 trial
Notification of the permanent closure of the ALC3 trial; A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).
 
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia.
Read More
Published:
Category: Trials
Permanent Trial Closure: REC3
Notification of the permanent trial closure of REC3 (SWOG S1500) A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (PAPMET) trial.
 
This randomized phase II trial studied how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body.
Read More


Published:
Category: Group updates
CCTG Annual Spring Meeting of Participants May 3 - 5 - meeting in progress

The CCTG Annual Spring Meeting of Participants will be held Friday, May 3 to Sunday, May 5 at the Chelsea Hotel in Toronto. Here are some updates if you are planning on joining us.

Meeting Invitations

If you are planning meetings and/or attending the Spring Meeting be sure to read your Invitation carefully so you are clear on the funding support associated with your Invitation.

Read More
Published:
Category: Group updates
CCTG Recognition Awards - Call for Nominations
The Canadian Cancer Trials Group is seeking nominations for the 2024 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Group. Read More